Back to News
Market Impact: 0.25
ImPact Biotech Announces Completion of Treatment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC and Positive Regulatory Updates
Source: GlobeNewswire
Healthcare & Biotech
The company reported successful treatment of 91 patients, with consistent safety and efficacy observed to date. Interim clinical data are scheduled for presentation at the ESMO Congress in October 2026, providing a forthcoming catalyst but no detailed efficacy metrics in the announcement.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features, UI Improvements, and Chat Optimizations
- Selecting an AI Research Platform for Institutional Investors